Clinical trials: Recurrent Lung Small Cell Carcinoma
Non-small Cell Lung Cancer
Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.
This study is designed as a multi-cohort trial based on various patient biomarkers study with the potential to include new study treatment in the future.
- Trial name
- REVIVE (NCT07279935)
- Testing
- Osimertinib+cisplatin or carboplatin + pemetrexed Edit
- Where
- 32 sites in China
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Lung Cancer, Non-Small Cell Lung Cancer
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
This is a study of experimental medication BMS-986205 given with Nivolumab with or without chemotherapy compared to chemotherapy in participants with previously untreated stage IV or recurrent non-small cell lung cancer.
- Trial name
- NCT03417037
- Testing
- BMS-986205, Nivolumab, Chemotherapy
- Where
- 83 sites in United States, Australia and 15 more
- Sponsor
- Bristol-Myers Squibb
Solid Tumors
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
The purpose of this study is to determine the safety and tolerability of ME-344 when given in combination with Hycamtin® in patients with solid tumors
- Trial name
- NCT02100007
- Testing
- ME-344, Topotecan
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 46 people
- Sponsor
- MEI Pharma, Inc.
SCLC
Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer
Adult patients with small-cell lung cancer (SCLC) will be treated with nivatrotamab a monoclonal anti GD2×CD3 bispecific antibody to investigate the safety and tolerability of the drug.
- Trial name
- NCT04750239
- Testing
- Nivatrotamab
- Where
- 7 sites in United States
- Volunteers
- 3 people
- Sponsor
- Y-mAbs Therapeutics
Metastatic Castration-resistant Prostrate Cancer, Renal Cell Carcinoma
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
The purpose of this study is to determine the safety and effectiveness of MDX-1106 in patients with certain types of cancer. Another purpose is to determine how MDX-1106 is absorbed and distributed within the body, and how it's…
- Conditions
- Metastatic Castration-resistant Prostrate Cancer, Renal Cell Carcinoma, Metastatic Melanoma, Non-small Cell Lung Cancer
- Trial name
- MDX1106-03 (NCT00730639)
- Testing
- BMS-936558 (MDX-1106)
- Where
- 13 sites in United States
- Volunteers
- 395 people
- Sponsor
- Bristol-Myers Squibb
Lung Cancer
Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Lometrexol may stop or slow the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Folic acid may be effective in preventing or lessening the side effects of lometrexol.
- Trial name
- NCT00033722
- Testing
- folic acid, lometrexol
- Where
- 7 sites in United States
- Sponsor
- Tularik
Non-small Cell Lung Carcinoma (NSCLC), Melanoma
Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)
The purpose of this study is to evaluate the safety and tolerability of humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 (CM-24 [MK-6018]), administered intravenously as monotherapy and in combination with…
- Conditions
- Non-small Cell Lung Carcinoma (NSCLC), Melanoma, Bladder Cancer, Colorectal Cancer
- Trial name
- NCT02346955
- Testing
- CM-24 (MK-6018), Pembrolizumab (MK-3475)
- Where
- 3 sites in United States, Israel
- Volunteers
- 27 people
- Sponsor
- Famewave Ltd.
Small Cell Carcinoma of Lung
A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
Lung cancer remains the leading cause of cancer deaths worldwide; in 2022, there were approximately 2.48 million new cases and 1.8 million deaths from lung cancer globally.
- Trial name
- NCT07550842
- Testing
- BL0020, Toripalimab
- Where
- 8 sites in China
- Volunteers
- 33 people
- Sponsor
- Shanghai Best-Link Bioscience, LLC
Non-Small Cell Lung Cancer
A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer
This single arm study will assess the feasibility of using Avastin plus platinum-based chemotherapy (cisplatin-gemcitabine or carboplatin-paclitaxel) in patients with advanced or recurrent squamous non-small cell lung cancer who…
- Trial name
- NCT00404703
- Testing
- bevacizumab [Avastin], Platinum-based chemotherapy
- Where
- 25 sites in Australia, Belgium and 8 more
- Volunteers
- 37 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer
A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC
A Phase 1b study for participants with Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) to participate in 1 of 2 portions of this study.
- Trial name
- PRIMAL (NCT02346370)
- Testing
- PEGylated recombinant human hyaluronidase PH20, Docetaxel
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- Halozyme Therapeutics
Urinary Bladder Neoplasms, Carcinoma, Transitional Cell
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
The purpose of the study is to evaluate the safety and to define the Maximal Tolerated Dose (MTD) or the Maximal Administered Dose (MAD) of oral azacitidine as a single agent and in combination with carboplatin (CBDCA) or…
- Conditions
- Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ovarian Neoplasms, Fallopian Tube Neoplasms
- Trial name
- NCT01478685
- Testing
- CC-486, Carboplatin, ABI-007
- Where
- 13 sites in United States, France and 2 more
- Volunteers
- 169 people
- Sponsor
- Celgene
Non-Small Cell Lung Cancer
A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan
The purpose of this observational study is to assess the effectiveness and safety of Nivolumab plus Ipilimumab with or without chemotherapy as first-line treatment for participants with untreated advanced or recurrent NSCLC in…
- Trial name
- LIGHT-NING (NCT05161325)
- Where
- Japan
- Volunteers
- 525 people
- Sponsor
- Bristol-Myers Squibb
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
NSCLC
A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate the efficacy and safety of BMS-986315 plus nivolumab in combination with platinum-based doublet chemotherapy (PDCT) versus nivolumab in combination with PDCT in the first-line treatment of…
- Trial name
- NCT06094296
- Testing
- BMS-986315, Nivolumab, Pemetrexed
- Where
- 8 sites in United States, Australia
- Volunteers
- 1 people
- Sponsor
- Bristol-Myers Squibb
Small Cell Lung Cancer
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
This study is designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
- Trial name
- IDeate-Lung02 (NCT06203210)
- Testing
- Ifinatamab deruxtecan, Topotecan, Amrubicin
- Where
- 229 sites in United States, Australia and 21 more
- Volunteers
- 540 people
- Sponsor
- Daiichi Sankyo
Non Small Cell Lung Cancer
Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
This trial is a multicenter, open-label, randomized, Phase III study in patients with recurrent or progressive Non-Small Cell Lung Cancer (NSCLC) after failure of an initial platinum-based chemotherapy.
- Trial name
- NCT00095199
- Testing
- Pemetrexed, Cetuximab, Docetaxel
- Where
- 67 sites in United States, Canada
- Volunteers
- 939 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumors, Breast Cancer Recurrent
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity…
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer, High-grade Serous Ovarian Carcinoma
- Trial name
- NCT06799065
- Testing
- ATX-295, ATX-295 and bevacizumab (or biosimilar)
- Where
- 11 sites in United States
- Volunteers
- 218 people
- Sponsor
- Accent Therapeutics
Neoplasms
Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors
The key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors.
- Trial name
- ARCS-Multi (NCT03102320)
- Testing
- Cisplatin, Gemcitabine, Anetumab ravtansine (BAY94-9343)
- Where
- 72 sites in United States, Australia and 10 more
- Volunteers
- 173 people
- Sponsor
- Bayer
Carcinoma, Non-Small-Cell Lung
Observational Study to Evalute the Efficacy and Safety of Avastin (Bevacizumab) in Addition to Platinum-Based Chemotherapy for First-Line Treatment of Participants With Non-Small Cell Lung Cancer
The purpose of this study is to examine the efficacy of Bevacizumab in addition to platinum-based chemotherapy for first-line treatment of participants with advanced stage (IIIB/IV) non-small cell lung cancer (NSCLC) other than…
- Trial name
- AVALANCHE (NCT03170284)
- Testing
- Bevacizumab
- Where
- 33 sites in Hungary
- Volunteers
- 150 people
- Sponsor
- Hoffmann-La Roche
Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC)
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
This is a multicenter, open-label Phase IIa clinical study to evaluate the efficacy and safety of B1962 in the treatment of ad-vanced solid tumors.
- Conditions
- Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers, Small Cell Lung Cancer
- Trial name
- NCT06724263
- Testing
- B1962
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.